Digest Network Come funziona
Network
/
Società
Id
Non verificato

Idorsia Pharmaceuticals Ltd

Di cosa scriviamo

Annunci EconomiciFarmaceutica

52 comunicati stampa

Guarda tutti i comunicati
10/11/2025
Farmaceutica
Annunci Economici
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
05/11/2025
Farmaceutica
Annunci Economici
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
29/10/2025
Farmaceutica
Annunci Economici
QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/10/2025
Farmaceutica
Annunci Economici
Idorsia successfully completes an upsized offering of shares – funding the company to overall profitability
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
09/10/2025
Farmaceutica
Annunci Economici
Idorsia launches an offering of registered shares – to fund the company to overall profitability
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
21/09/2025
Farmaceutica
Annunci Economici
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
18/09/2025
Farmaceutica
Annunci Economici
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
10/09/2025
Farmaceutica
Annunci Economici
Idorsia shares new analyses of daridorexant for patients with insomnia at World Sleep 2025
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
08/09/2025
Farmaceutica
Annunci Economici
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0
04/09/2025
Farmaceutica
Annunci Economici
Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
Fonte
Idorsia Pharmaceuticals Ltd
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0